

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Presently Amended) A [synergistic] therapeutic synergistic pharmaceutical composition for solid tumors comprising an effective amount of camptothecin, or a camptothecin derivative, in combination with an effective amount of a topoisomerase II inhibitor, wherein said composition provides a therapeutic synergistic effect in the treatment of solid tumors.
2. (Presently Amended) A [synergistic] therapeutic synergistic composition for solid tumors comprising an effective amount of CPT-11 in combination with an effective amount of a topoisomerase II inhibitor, wherein said composition provides a therapeutic synergistic effect in the treatment of solid tumors.
3. (Original) The composition according to one of claims 1 or 2, wherein said topoisomerase II inhibitor is an anthracycline antibiotic.
4. (Original) The composition according to claim 3, wherein said antibiotic is doxorubicin.
5. (Original) The composition according to claim 3, wherein said antibiotic is daunorubicin.
6. (Original) The composition according to one of claims 1 or 2, wherein said topoisomerase II inhibitor is an epipodophyllotoxin.
7. (Original) The composition according to claim 6, wherein said epipodophyllotoxin is etoposide.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

8. (Original) The composition according to claim 6, wherein said epipodophyllotoxin is teniposide.

9. (Original) The composition according to one of claims 1 or 2, wherein said solid tumor is a mammary adenocarcinoma.

10. (Original) The composition according to one of claims 1 or 2, wherein said solid tumor is a pancreatic ductal adenocarcinoma.

11. (Presently Amended) A [synergistic] therapeutic synergistic pharmaceutical composition for solid tumors comprising an effective amount of at least two agents, wherein a first agent is CPT-11 and a second agent is doxorubicin, wherein said composition provides a therapeutic synergistic effect in the treatment of solid tumors.

12. (Original) The composition according to claim 11, wherein the at least two agents are administered simultaneously, semi-simultaneously, or separately.

13. (Presently Amended) A method of treating a solid tumor, comprising administering an effective amount of camptothecin, or a camptothecin derivative, as a first agent, in combination with an effective amount of a topoisomerase II inhibitor as a second agent, wherein the agents are administered simultaneously, semi-simultaneously, or separately, and wherein said first and second agents provide a therapeutic synergistic effect in the treatment of said solid tumor.

14. (Original) The method according to claim 13, wherein the camptothecin derivative is CPT-11, and the topoisomerase II inhibitor is an anthracycline antibiotic.

15. (Original) The method according to claim 14, wherein said antibiotic is doxorubicin.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

16. (Original) The method according to claim 14, wherein said antibiotic is daunorubicin.
17. (Original) The method according to claim 13, wherein the camptothecin derivative is CPT-11, and the topoisomerase II inhibitor is an epipodophyllotoxin.
18. (Original) The method according to claim 17, wherein said epipodophyllotoxin is etoposide.
19. (Original) The method according to claim 17, wherein said epipodophyllotoxin is teniposide.
20. (Original) The method according to any one of claims 13-19, wherein the camptothecin derivative is administered orally.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com